654 related articles for article (PubMed ID: 34969393)
41. Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.
Phan AT; Gukasyan J; Arabian S; Wang S; Neeki MM
Cureus; 2021 May; 13(5):e15280. PubMed ID: 34194882
[TBL] [Abstract][Full Text] [Related]
42. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
Baum A; Ajithdoss D; Copin R; Zhou A; Lanza K; Negron N; Ni M; Wei Y; Mohammadi K; Musser B; Atwal GS; Oyejide A; Goez-Gazi Y; Dutton J; Clemmons E; Staples HM; Bartley C; Klaffke B; Alfson K; Gazi M; Gonzalez O; Dick E; Carrion R; Pessaint L; Porto M; Cook A; Brown R; Ali V; Greenhouse J; Taylor T; Andersen H; Lewis MG; Stahl N; Murphy AJ; Yancopoulos GD; Kyratsous CA
Science; 2020 Nov; 370(6520):1110-1115. PubMed ID: 33037066
[TBL] [Abstract][Full Text] [Related]
43. Passive immune therapies: another tool against COVID-19.
Estcourt LJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):628-641. PubMed ID: 34889410
[TBL] [Abstract][Full Text] [Related]
44. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
45. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
46. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
[TBL] [Abstract][Full Text] [Related]
47. Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia.
Hegazy AN; Krönke J; Angermair S; Schwartz S; Weidinger C; Keller U; Treskatsch S; Siegmund B; Schneider T
BMC Infect Dis; 2022 Jun; 22(1):537. PubMed ID: 35692034
[TBL] [Abstract][Full Text] [Related]
48. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
49. Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies.
Janssen M; Leo A; Wolf C; Stenzinger M; Bartenschlager M; Brandt J; Sauer S; Schmitt M; Dreger P; Schlenk RF; Denkinger CM; Müller-Tidow C
Int J Cancer; 2024 Aug; 155(4):618-626. PubMed ID: 38721724
[TBL] [Abstract][Full Text] [Related]
50. Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.
Mikulska M; Sepulcri C; Dentone C; Magne F; Balletto E; Baldi F; Labate L; Russo C; Mirabella M; Magnasco L; Di Grazia C; Ghiggi C; Raiola AM; Giacobbe DR; Vena A; Beltramini S; Bruzzone B; Lemoli RM; Angelucci E; Bassetti M
Clin Infect Dis; 2023 Jul; 77(2):280-286. PubMed ID: 36976301
[TBL] [Abstract][Full Text] [Related]
51. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
Belote A; Reece S; Robinson S; Jensen H; CarlLee S; Clark M; Parnell S; Geels C; Newton J
Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):210-213. PubMed ID: 35920868
[TBL] [Abstract][Full Text] [Related]
52. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience.
Verderese JP; Stepanova M; Lam B; Racila A; Kolacevski A; Allen D; Hodson E; Aslani-Amoli B; Homeyer M; Stanmyre S; Stevens H; Garofalo S; Henry L; Venkatesan C; Gerber LH; Motew SJ; Jones JS; Younossi ZM
Clin Infect Dis; 2022 Mar; 74(6):1063-1069. PubMed ID: 34166513
[TBL] [Abstract][Full Text] [Related]
53. Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
Miyazato Y; Yamamoto K; Nakaya Y; Morioka S; Takeuchi JS; Takamatsu Y; Maeda K; Kimura M; Sugiura W; Mitsuya H; Yano M; Ohmagari N
J Infect Chemother; 2022 Jul; 28(7):991-994. PubMed ID: 35337728
[TBL] [Abstract][Full Text] [Related]
54. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.
Wolf J; Abzug MJ; Wattier RL; Sue PK; Vora SB; Zachariah P; Dulek DE; Waghmare A; Olivero R; Downes KJ; James SH; Pinninti SG; Yarbrough A; Aldrich ML; MacBrayne CE; Soma VL; Grapentine SP; Oliveira CR; Hayes M; Kimberlin DW; Jones SB; Bio LL; Morton TH; Hankins JS; Maron GM; Timberlake K; Young JL; Orscheln RC; Schwenk HT; Goldman DL; Groves HE; Huskins WC; Rajapakse NS; Lamb GS; Tribble AC; Lloyd EC; Hersh AL; Thorell EA; Ratner AJ; Chiotos K; Nakamura MM
J Pediatric Infect Dis Soc; 2021 May; 10(5):629-634. PubMed ID: 33388760
[TBL] [Abstract][Full Text] [Related]
55. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.
Loo YM; McTamney PM; Arends RH; Abram ME; Aksyuk AA; Diallo S; Flores DJ; Kelly EJ; Ren K; Roque R; Rosenthal K; Streicher K; Tuffy KM; Bond NJ; Cornwell O; Bouquet J; Cheng LI; Dunyak J; Huang Y; Rosenbaum AI; Pilla Reddy V; Andersen H; Carnahan RH; Crowe JE; Kuehne AI; Herbert AS; Dye JM; Bright H; Kallewaard NL; Pangalos MN; Esser MT
Sci Transl Med; 2022 Mar; 14(635):eabl8124. PubMed ID: 35076282
[TBL] [Abstract][Full Text] [Related]
56. Combined REGN-COV2 Antibody Therapy Immediately Prevented a Patient with Refractory Type 1 Autoimmune Pancreatitis from Contracting SARS-CoV-2 during the Sixth Wave in Japan.
Katsuo C; Kubota K; Tanaka K; Kurita Y; Nakajima A
Intern Med; 2023; 62(12):1765-1770. PubMed ID: 37316279
[TBL] [Abstract][Full Text] [Related]
57. Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
Ferré VM; Peiffer-Smadja N; Kramer L; Coppée R; Kante A; Debarge M; Choquet C; Saint Joannis T; Bouzid D; Messika J; Le Grand J; Thy M; Kernéis S; Descamps D; Visseaux B; Ghosn J
Microbiol Spectr; 2022 Oct; 10(5):e0215222. PubMed ID: 36125289
[TBL] [Abstract][Full Text] [Related]
58. Casirivimab-imdevimab monoclonal antibody treatment for an immunocompromised patient with persistent SARS-CoV-2 infection: a case report.
Sam KS; Khosla P; Taneja V; Dessai R
Commun Med (Lond); 2024 Jun; 4(1):103. PubMed ID: 38824216
[TBL] [Abstract][Full Text] [Related]
59. Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge.
Bartalucci C; Limongelli A; Nicolini LA; Ponzano M; Tigano S; Farinella ST; Carrega G; Malerba G; Magnè F; Balletto E; Giacobbe DR; Riccio G; Cenderello G; Taramasso L; Bruzzone B; Vena A; Di Biagio A; Mikulska M; De Maria A; Dentone C; Bassetti M
J Chemother; 2024 Jul; 36(4):283-290. PubMed ID: 38095569
[TBL] [Abstract][Full Text] [Related]
60. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]